This trial is evaluating whether commercially available lansoprazole will improve 1 primary outcome and 6 secondary outcomes in patients with Asthma. Measurement will happen over the course of Week 0 (baseline) through Week 26.
This trial requires 110 total participants across 2 different treatment groups
This trial involves 2 different treatments. Commercially Available Lansoprazole is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
"Common treatments for gastroesophageal reflux include medications used in the treatment of H. pylori (proton pump inhibitors, clarithromycin, levofloxacin, and amoxicillin) and prokinetics (metoclopramide, domperidone, and nisoldipine). Less common options include proton pump inhibitors, achlorhydria stimulants (such as domperidone), and pyridostigmine bromide." - Anonymous Online Contributor
"There is a low probability that GER could be cured. In patients with GER symptomatically managed, symptoms can often be treated with medication. It is suggested that patients with gastric reflux and symptoms be re-examined for esophageal reflux, gastric reflux, reflux esophagitis and/or Barrett's esophagus. Furthermore, there is a good chance that medication is not curative for patients with severe symptoms, and so alternative therapeutic techniques that may improve symptoms are appropriate." - Anonymous Online Contributor
"If symptoms do not resolve within 2 weeks, then symptoms of reflux should be followed up. If symptoms remain, this has potential consequences. Symptoms include headache, [back pain](https://www.withpower.com/clinical-trials/back-pain), abdominal pain, and nausea and vomiting (due to refluxed gastric contents)." - Anonymous Online Contributor
"Gastrointestinal symptoms are commonly reported in adult populations, and studies in children indicate that prevalence is as high as 6%. A definition of gastroesophageal reflux disease does not appear to exist, and the condition is still primarily diagnosed by endoscopy. At present, it appears that gastroesophageal reflux is not a serious or disabling disease." - Anonymous Online Contributor
"Acid reflux causes about half of oesophageal mucosal erosions. A correlation has also been established between reflux-induced damage and the presence of autoimmune disease. The precise pathogenesis of these disorders is still a matter of discussion between various researchers." - Anonymous Online Contributor
"Approximately 5 billion people were impacted by GERD based on either diagnosis or treatment. GERD was the most common reason for visit to the physician among adults in the USA. GERD may be under-reported among patients with asthma, and as a reason for visit to the physician." - Anonymous Online Contributor
"Lansoprazole was commonly used in combination with other drugs and is considered appropriate for use in combination therapy with antibiotics for eradicating H. pylori. There is no evidence to show that the efficacy of lansoprazole was worse when used in combination therapy with other drugs." - Anonymous Online Contributor
"In most studies with commercial lansoprazole, patients who received lansoprazole had statistically significantly lower discontinuation rates than placebo-treated patients. It is plausible that lower treatment discontinuation rates were primarily due to decreased GI side effects with lansoprazole compared with placebo treatment." - Anonymous Online Contributor
"Clinical trials are an important tool to improve health outcomes and reduce health care costs for people with gastroesophageal reflux disease. A key prerequisite for trial registration, including patient and professional selection guidelines, was not evident in the gastroenterology literature. Clinical trials are usually performed in people with severe disease, which may be uncommon among people with the gastroesophageal reflux disease. There is a need for a process for identifying persons who might benefit from clinical trials." - Anonymous Online Contributor
"The majority of participants received lansoprazole 40 mg/d, with most of them in good adherence. The commercial product name did not vary from that of the brand name, and there were minimal differences between both in absorption, absorption, maximum concentration, and AUC." - Anonymous Online Contributor
"There is compelling evidence supporting the effectiveness of treatment for GERD by PPI plus H2 blocker or antacids alone. The PPI does not appear to be necessary in those who achieve normalization of pH but has been shown to reduce the likelihood of recurrence. PPI and H2 blocker combination treatment options offer both effective symptom control and eradication of oesophageal acid reflux disease, without significant adverse effect. However, there is no evidence of PPI or H2 blocker dependence. More studies are required to make reliable predictions in the future of this evolving treatment option." - Anonymous Online Contributor
"Recent findings of this randomized, double-blind, crossover trial suggest that lansoprazole 20 mg is effective at controlling reflux symptoms. Because lansoprazole is absorbed in a rapid and sustained manner at gastrointestinal pH (pH 3), this study supports additional investigation to identify dosage regimens that minimize the gastrointestinal symptoms." - Anonymous Online Contributor